Everwell Health Acquires Celadrin: Expanding Portfolio with Plant-Based Mobility and Skin Solutions

Everwell Health Acquires Celadrin, expanding its product portfolio with plant-based cetylated fatty acid technology and esterified fatty acid compounds. This acquisition includes all assets related to the Celadrin brand, which is known for its benefits in joint comfort, increased mobility, and skin care for both humans and pets. This move strengthens Everwell’s position in the growing supplement and wellness markets.

What the Acquisition Means for Everwell Health

Everwell Health’s acquisition of Celadrin allows the company to offer more solutions targeting mobility, joint comfort, and skin health. Cetylated fatty acid creams are known to reduce pain and improve joint function, while esterified fatty acids are valued for softening and smoothing skin. Everwell Health sees increasing demand for these benefits in both the supplement and beauty markets.

Jordan Miller, VP of Marketing at Everwell Health, notes the growth in these markets. “Joint health supplements have grown nearly 11% CAGR from 2022 to 2024,” says Miller. “Skin and beauty product launches have also seen a 13% CAGR.” This demonstrates a clear demand for innovative solutions aimed at improving mobility, flexibility, and overall skin health.

The Celadrin Brand and Its Benefits

The acquisition includes all Celadrin assets, a well-known brand sold globally in over a dozen countries. Celadrin products promote joint health, flexibility, and comfort by modulating the body’s inflammatory response and supporting cell membrane function. Clinical studies back the brand, confirming its benefits for joint health and skin aging when used topically.

Celadrin’s popularity extends to pet care, as its formula is used to promote mobility and skin health for animals. Everwell Health is excited about expanding the Celadrin ingredient into the growing pet care market, where quality nutrition and preventive care are top priorities.

Market Growth and Consumer Demand for Mobility and Skin Solutions

Everwell Health sees massive potential in the anti-aging and mobility markets. According to Innova Market Insights, 33% of global consumers prioritize anti-aging features in skincare. This trend has contributed to a 5% global market growth in anti-aging product launches from 2019 to 2023. Additionally, 54% of North American consumers are interested in mobility products, even if they aren’t experiencing symptoms.

Steve Rosenman, CEO of Everwell Health, is optimistic about the future: “We plan to support our customers with scientific investments and extensive marketing capabilities as we expand the Celadrin ingredient.” This acquisition is just the beginning, as Everwell Health continues to expand its innovation pipeline.

Explore more news on this website to stay updated on the latest acquisitions and trends in the wellness and pet care markets!